The vulnerability and limitations of impact factor in evaluating quality
We enjoyed reading the article by Chew et al. (JRSM 2007 ; 100: 142-150). 1 The article clearly highlights the vulnerability and limitations of impact factor in evaluating the quality of journals. A well-informed and careful use of this impact data is thus essential. Thompson Scientific agrees that there are limitations attached to impact factors, and emphasize that there is no substitute for informed peer review. 2 Many scholars have suggested that Thompson should count citations only to original research articles, eliminating the problem of news, stories, editorials, reviews and other kind of material which can influence the citation rates falsely. In 2006, Bollen et al. proposed the PageRank algorithm used by Google to distinguish the quality of citations and hence improve impact factor calculations. 3 There is a definite need for other methods for analyzing bibliographic material and assessing its quality. Instead of citations, as being used in calculating impact factor, one can ask the peer reviewers to rate an accepted article over a score of hundred at the time of its review. Since articles are usually evaluated on several quantitative and qualitative parameters-for example, originality, clarity, content, methodology, discussion-this score will give a fair idea of 'quality' of the article. Scores from two or more blind reviewers will increase the reliability of the score. The score thus calculated can be published along with the accepted article. Since the editorials, reviews, letters, etc., are not original articles, this score cannot be calculated for the same. In addition, as your editorial suggests, 1 impact factorsat worst an unscientific and non-transparent method to capture markets and advertisers-may also fall in this category. We welcome additions from readers to this dataset. There are many candidates. For example, do any multinational food companies sponsor and subtly influence nutrition journals? Might any military agent covertly sponsor a peace journal?
These examples, real and hypothetical, support the case that publishers should periodically declare their own conflicts of interest. Your editorial goes very close to declaring (like the BMJ: http://resources.bmj.com/bmj/ about-bmj/declaration-of-competing-interests) that your journal has no such conflicts of interest to hide. As with the JRSM ('flourishing by entirely reputable means'), journals with nothing to hide need not fear making such a declaration. Perhaps an indicator of publisher transparency could even be woven into journal impact factors! A way to think of these problems is in terms of public and private goods. The failure of socialist economies to achieve a semblance of utopia lies, in part, on an insufficient appreciation of private goods and the human need for rewards in exchange for risk, inventiveness and hard work. But globally, the pendulum to private goods has swung too far. Public goods are vital for well-being and for sustainability, and it is folly to think that they can be largely or even fully replaced by private goods, even if supplied in copious quantities. Indeed, many public goods, such as freedom of speech, clean air and an absence of nuclear weapons, have no plausible private substitute at all.
We recognise that private goods, such as advertising and fees for journal offprints, are a legitimate mechanism to offset the many costs of publishing. Equally clearly, the public good of the scientific discourse, unencumbered as far as possible by unseen influence, is essential if our civilization is to flourish. Long ago, gentlemen observed codes of conduct which were as much unspoken as stated. Professionalism once meant that certain norms would (almost) unquestionably be observed. The erosion of these standards, combined with a supposedly greater sophistication of the audience, has in recent times forced authors and reviewers to declare real and perceived conflicts of interest. We welcome this. But publishers are clearly also contaminated by these same powerful global forces. It is time for all publishers to declare their own conflicts of interest, both real and reasonably perceived as such.
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Lariam and Halfan
Ashley Croft 1 has performed a service in exposing the disgraceful failure to test properly the antimalarial drugs Lariam (mefloquine) and Halfan (halofantrine) (JRSM 2007;100:170-174). The side-effects of these drugs were not widely recognized until the mid-1990s, but incredibly, a randomized controlled study was not undertaken until 2001! 2 In 1995, my wife and I, on our way back from Tristan da Cunha, were on board RMS St Helena, which called at The Gambia, where we had a day ashore. For this reason we had been advised to take malaria prophylaxis. We shared a table with the ship's doctor, who remarked on the number of passengers, mainly women, who were complaining of depression: he attributed this to the Lariam which they had been prescribed. We had put our faith in chloroquine and proguanil instead.
Unfortunately, the ship's doctor did not think to send an adverse reaction report, which was a pity since such a report might have produced action earlier than 2001.
I was astonished to find that mefloquine (but not halofantrine) was still listed in the 
